|
KMID : 1141720210090020069
|
|
폐쇄성폐질환
2021 Volume.9 No. 2 p.69 ~ p.72
|
|
|
Biomarker of COPD
|
|
Koo Hyeon-Kyoung
|
|
|
Abstract
|
|
|
|
COPD is a heterogenous disease with various clinical manifestation attributable to diverse pathophysiology. Biomarker is defined as characteristic that is objectively measured and evaluated as an indicator of normal biological process, pathogenic process, or pharmacologic responses to therapeutic intervention. There had been intensive efforts to discover novel biomarkers to monitor disease activities, predict prognosis, and select therapeutic targets for disease modification. However, only one blood biomarker, fibrinogen, was qualified by US Food and Drug Administration as a drug development tool so far. Recently, blood eosinophil count has emerged as a COPD biomarker to guide the use of inhaled corticosteroid (ICS) in group D patients since 2019 GOLD guideline. We tried to summarize the evidences to look over the latest publication related to topics about biomarker of COPD to better understand the pathophysiology and treatment option.
|
|
|
KEYWORD
|
|
|
COPD, Biomarker, Eosinophil, GOLD
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|